Alumis Inc.
ALMS
Peringkat dalam Saham
#10425
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Harga Saham
$6.15
Terakhir disinkronkan: 2026-10-16
Kapitalisasi Pasar
$795.38M
Perubahan (1 hari)
-2.61%
Perubahan (1 tahun)
170.70%
Negara
US
Perdagangan Alumis Inc. (ALMS)
Kategori
Healthcare
Kapitalisasi pasar dari Alumis Inc.(ALMS)
Kapitalisasi Pasar: $795.38M
Per October 2026, Alumis Inc. memiliki kapitalisasi pasar sebesar $795.38M. Ini menjadikan Alumis Inc. sebagai perusahaan 10425th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Alumis Inc. dari 2023 hingga 2026
ALMS dibandingkan dengan 5 teratas stocks paling populer
